



Docket No.: NIH173.001C1

Customer No.: 20,995

AMENDMENT / RESPONSE TRANSMITTAL

Applicant : Wang et al.
App. No. : 10/099,782
Filed : March 14, 2002
For : METHOD OF IDENTIFYING
A COMPOUND THAT
MODULATES BINDING OF
SERUM AMYLOID A (SAA)
TO A FPRL1 RECEPTOR (AS
AMENDED)
Examiner : Turner, Sharon L.
Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 25, 2004

(Date)

Nancy W. Versko, Reg. No. 36,298

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

(X) Amendment and Response to Office Action in 12 pages.
(X) The interaction of FPRL1 with serum amyloid A (SAA) in 1 page.

The fee has been calculated as shown below:

FEE CALCULATION				
FEE TYPE		FEE CODE	CALCULATION	TOTAL
Total Claims	10 - 28 = 0	1202 (\$18)	0 x 18 =	\$0
Independent Claims	1 - 8 = 0	1201 (\$86)	0 x 86 =	\$0
1 Month Extension		1251 (\$110)		\$110
			TOTAL FEE DUE	\$110

(X) An extension of time is hereby requested by payment of the appropriate fee indicated above.
(X) A check in the amount of \$110 is enclosed.
(X) Return prepaid postcard.

NIH173.001C1



1647
PATENT
JRW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Wang et al.
Appl. No. : 10/099,782
Filed : March 14, 2002
For : METHOD OF IDENTIFYING A COMPOUND
THAT MODULATES BINDING OF SERUM
AMYLOID A (SAA) TO A FPRL1 RECEPTOR
(AS AMENDED)
Examiner : Turner, Sharon L.
Group Art Unit : 1647

AMENDMENT AND RESPONSE TO OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed February 25, 2004, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 6 of this paper.

Remarks/Arguments begin on page 7 of this paper.